KaliVir

KaliVir Immunotherapeutics aims to pioneer a unique and novel cancer treatment method by leveraging the natural ability of viruses to replicate and kill cancer cells. This approach is known as oncolytic virus immunotherapy. KaliVir's cutting-edge, next-generation oncolytic virus immunotherapy program combines internally developed technologies and is licensed from the world-class oncolytic virus and immunotherapy research program at the University of Pittsburgh.